Nonparametric regression for cost-effectiveness analyses with observational data - a tutorial

Jonas Esser ​,​, Mateus Maia ​,​, Judith E. Bosmans, Johanna Maria van Dongen · 2025

Read Nonparametric regression for cost-effectiveness analyses with observational data - a tutorial by Jonas Esser ​,​, Mateus Maia ​,​, Judith E. Bosmans, Johanna Maria van Dongen (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/arxiv-2507-03511.txt.

Introduction

Jonas Esser and co-authors offer, in a 2025 tutorial paper, a guide to flexible regression methods for judging whether a treatment is worth its extra cost when only observational data exist. Health choices often pit a better but pricier option against a cheaper one. In such data, hidden bias can warp simple estimates of costs and effects.

Many studies still lean on plain regression or matching, which can mislead. The tutorial focuses on a tree-based Bayesian method that bends to complex data patterns. It gives code and step-by-step advice for use in cost studies. The authors argue the method yields sturdier, more believable estimates for real policy choices.

Catalog record

CREATORJonas Esser ​,​, Mateus Maia ​,​, Judith E. Bosmans, Johanna Maria van Dongen
YEAR2025
COLLECTIONPAPERS
FORMATTXT
FILE SIZE47 KB
VERSION1.0
LICENSEhttp://creativecommons.org/licenses/by/4.0/
RIGHTSCC BY
SOURCEarXiv

Source: https://arxiv.org/abs/2507-03511

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Nonparametric regression for cost-effectiveness analyses with observational data - a tutorial Jonas Esser ​,​, Mateus Maia ​,​, Judith E. Bosmans, Johanna Maria van Dongen Abstract Healthcare decision-making often requires selecting among multiple treatment options under budget constraints, particularly when one option is more effective but also more costly. Cost-effectiveness analysis (CEA) provides a framework for evaluating whether the health benefits of a treatment justify its additional costs. A key component of a CEA is the estimation of treatment effects on both health outcomes and costs, which becomes challenging when using observational data, due to potential confounding. While advanced causal inference methods exist for use in such circumstances, their adoption in CEAs remains limited, with many studies relying on overly simplistic methods such as linear regression or propensity score matching. In this paper, we address this gap by introducing cost-effectiveness researchers to modern nonparametric regression models, with a particular focus on Bayesian Additive Regression Trees (BART). We provide guidance on how to implement BART in CEAs, including code examples, and discuss its advantages in producing more robust and credible estimates from observational data. † † orcid: 0009-0005-4964-5525 † † orcid: 0000-0001-7056-386X † † orcid: 0000-0002-1443-1026 † † orcid: 0000-0002-1606-8742 , , and ?? Faculty of Science, Health Economics and Health Technology Assessment, Vrije Universiteit Amsterdam,??; ??; ?? ?? School of Mathematics and Statistics, University of Glasgow,?? Key points • Estimating treatment effects in cost-effectiveness analyses (CEAs) requires careful adjustment for confounding, yet many studies still rely on linear regression and other simplistic methodology. • This paper introduces Bayesian Additive Regression Trees (BART) as a flexible, nonparametric alternative for CEAs, offering practical guidance and code to help researchers generate more credible and robust estimates. 1 Introduction A central challenge in healthcare decision-making is determining which interventions to implement or reimburse within the limits of constrained budgets. This often necessitates choosing between two or more competing treatment options for the same medical condition, where one treatment proves to be both more effective and more costly than the other. Cost-effectiveness analyses (CEAs) are designed to inform such choices by assessing whether the additional health gains of a treatment justify its additional costs. A key component of a CEA is the estimation of the treatment effects on both patients’ health outcomes and associated costs using available data. If cost-effectiveness data are obtained from a randomized trial, where treatment allocation does not depend on the patients’ baseline characteristics, the statistical estimation of treatment effects is relatively simple. If the data are observational, however, and treatment allocation is hence related to the patients’ baseline characteristics, the estimation procedure is much more complex. Despite the availability of several textbooks on the analysis of observational data ( Imbens and Rubin 2015 ; Aronow and Miller 2019 ; Hernán and Robins 2024 ) , appropriate methodology is not widely used in the field of CEA. That is, many researchers rely on simple linear regression or propensity score matching, preventing them from capturing complex, nonlinear relationships or interactions within the data. While there are some proposals for more sophisticated statistical methods in CEAs ( Kreif et al. 2013 ; Chen et al. 2024 ) , they still depend on restrictive parametric models, which may limit them from appropiately modeling complex data structures. We see several potential reasons for the reliance on such relatively simple models. One is simply researchers’ potential unawareness of useful alternatives, or of the advantages which these alternatives offer. Another is the added complexity of nonparametric models, with respect to both usage and interpretation. In this paper, we aim to enlargen the toolkit available to cost-effectiveness researchers, by providing an accessible guideline on how to use state-of-the-art nonparametric regression methods for CEAs. Our focus will be on the Bayesian Additive Regression Trees (BART) model, which has recently been extended for application in the cost-effectiveness setting. 2 Preliminaries We begin by explaining what researchers aim to learn from CEAs using observational data. Our presentation will be quite informal; a more rigorous version may be found in Esser et al. 2024 . We shall not consider more general issues in the analysis of observational data, such as well-defined patient populations, treatment options, follow-up periods and so on. Such aspects are important, arguably more important than the statistical aspects, but they apply to CEAs in exactly the same way as they do to other epidemiological analyses. We thus refer the reader to canonical sources on these issues, such as Hernán and Robins 2016 . In a typical CEA, the researcher is faced with two treatment options, t=0 and t=1 . Often the former is called the control , and the latter the intervention . The fundamental goal of a CEA is to estimate, given available data, the probability that the intervention is cost-effective, compared with the control. To make this possible, we consider two essential quantities: • \Delta_{c} , the average treatment effect on the costs . Put simply, \Delta_{c} tells us how much more we would need to pay per patient, on average, if every patient received the intervention instead of the control. It is typically expressed in the local currency which healthcare authorities are concerned with — for instance, the Dutch National Health Care Institute uses EUR ( Hakkaart-van Roijen et al. 2015 ) . • \Delta_{q} , the average treatment effect on the patient’s health 1 1 1 Instead of health many authors use the term effect here; see for example Drummond et al. 2015 . We avoid this terminology, since we consider it confusing: \Delta_{q} would then be the ”effect on the effect”. . This quantity tells us how much healthier the patients would be, on average, if every patient received the intervention instead of the control. The patients’ health can be measured in many different ways. Some are disease-specific, others are intentionally non-specific, in order to make the health state of patients comparable across different diseases. Of the latter, the most commonly used is the Quality-adjusted life year (QALY) ( Drummond et al. 2015 ) . As indicated above, we frequently encounter the situation that both treatment effects are positive, meaning that the intervention is both more effective and more expensive than the intervention. A natural question then arises: do the added health gains of the intervention justify the increase in costs? To answer this, we need to quantify how much we are willing to pay for an additional unit of health. This quantity is called the willingness-to-pay (WTP) and is customarily assigned the symbol \lambda . Example 1. Suppose that costs are measured in EUR, and \Delta_{c}=1000 ; health is measured in QALYs, and \Delta_{q}=0.1 . Then, by implementing the intervention, we gain an average health benefit of 0.1 QALYs per patient, while, having to pay an additional 1000 EUR. We hence need to pay 10000 EUR in exchange for one QALY gained (because 1000/0.1=10000 ). The intervention is cost-effective if and only if \lambda is greater than 10000 . In other words, the intervention is cost-effective if and only if \lambda*0.1-1000>0 . The decision process in the preceding example can be formalized by working with the the incremental net benefit (INB): \text{INB}_{\lambda}\coloneqq\lambda\Delta_{q}-\Delta_{c}. By putting a monetary value on health ( \lambda ) and checking

Read the complete text